The BWP in 1996 also initiated revision of existing guidance concerning vaccines (requirements for influenza and combination vaccines), medicinal products derived from blood and plasma (clotting factor concentrates, albumin and immunoglobulin control authority batch release) and issues about the potential risk of spongiform encephalopathy transmission via medicinal products (CPMP/ 384/ 96).